In August 2026, neuroscientists' attention was drawn to a new study showing that ibogaine—an alkaloid from the bark of the African plant Tabernanthe iboga—is capable of stimulating the repair of the myelin sheath of nerve fibers. This discovery goes beyond the substance's already known anti-addictive properties and points to the potential for neurorestoration in multiple sclerosis and white matter damage caused by opioids.
Ibogaine has been used for decades in the traditional medicine of West and Central Africa for ritual and medicinal purposes. In Western medicine, it is valued primarily for its ability to sharply reduce cravings for opiates and alleviate withdrawal symptoms after a single dose. However, recent work by Calvey and colleagues (2026) has revealed another mechanism: the substance increases the expression of genes and proteins responsible for myelin synthesis, which leads to the remyelination of damaged axons.
Chronic opioid use, including methadone, destroys the brain's white matter: levels of key myelin proteins decrease, and vacuoles and axonal spheroids appear. In multiple sclerosis, the loss of the myelin sheath disrupts signal conduction, causing coordination disorders, cognitive impairment, and muscle spasms. Ibogaine, by acting simultaneously on several receptor systems—glutamate, serotonin, sigma receptors, and nicotinic acetylcholine receptors—reduces glutamate toxicity and triggers metabolic processes that promote long-term neuroplasticity.
Unlike many psychedelics, whose effects are often reduced to acute altered states of consciousness, ibogaine demonstrates a delayed reparative effect. A single dose can trigger a cascade of changes that persist for weeks and months, which is especially important for patients with persistent neurological impairments. This raises the question of the boundary between "psychedelic therapy" and true neurorestoration.
Imagine an electrical cable with damaged insulation: signals pass through with interference or are lost entirely. According to preliminary data, ibogaine acts as a master repairman for this insulation—not just temporarily boosting the signal, but helping cells to "rewrap" axons with myelin. Such a mechanism explains why the substance can simultaneously affect addiction, PTSD symptoms, and neurodegenerative processes.
The study is still preliminary and requires confirmation in controlled clinical trials. Nevertheless, it fits into a growing body of data suggesting that some psychedelics are capable of not only altering perception but also triggering real structural changes in the brain. In the context of the opioid addiction epidemic and the growing prevalence of neurodegenerative diseases, this discovery forces a reconsideration of ibogaine's place in the arsenal of modern medicine.
It seems likely that the future of psychiatry and neurology will be linked not only to suppressing symptoms but also to activating the brain's internal recovery mechanisms—and ibogaine may become one of the keys to this process.
